Interview: António Portela, CEO, Bial Portugal
António Portela, CEO of Portugal’s flagship pharmaceutical company Bial, talks about the recent approval of Aptiom by the FDA, the first Portuguese drug to ever to be approved in the…
Founded in 1924, BIAL is today the biggest Portuguese pharmaceutical group with a team of about 900 collaborators, and with a strong commitment to R&D, internationalization and quality.
BIAL is also an international pharmaceutical group with business activities in more than 50 countries. Based in Portugal, Bial owns facilities in Spain—where a production unit and a R&D centre dedicated to allergic immunotherapy are situated—Italy, Mozambique, Panama, and other countries.
Strongly committed to therapeutic innovation, investing more than 20 percent of its turnover in R&D every year, BIAL Group has launched the first drug of Portuguese patent, an anti-epileptic. Available since 2009 in several European markets, under the brand Zebinix, this antiepileptic, eslicarbazepine acetate, has recently been approved by the regulator of the pharmaceutical market in the US, Food and Drug Administration (FDA), for commercialization in the United States under the brand Aptiom.
BIAL has also a second pharmaceutical for its own research, for the treatment of the Parkinson disease, which is already in an advanced development process (phase III of clinical development).
The company expects to introduce more new medicines and vaccines to the market in the next years, specifically in the central nervous system, the cardiovascular system and allergen immunotherapy, which will be an added impetus to its international expansion.
Since 2005 the Bial Group is a member of the “European Federation of Pharmaceutical Industries and Associations” (EFPIA), which has recognized Bial as a research and development pharmaceutical company capable of bringing new medicines to the world to improve human health and the quality of life of the populations.
Bial Group has also been distinguished by its support to several medical and scientific activities, namely through BIAL Foundation, having as outstanding events the BIAL Award and Scientific Research Grants, well recognized worldwide.
Bial Contact Info:
À Av. da Siderurgia Nacional
4745-457 S. Mamede do Coronado – Portugal
Phone: +351 22986 6100 | Fax: +351 22986 6190
www.bial.com | info@bial.com
António Portela, CEO of Portugal’s flagship pharmaceutical company Bial, talks about the recent approval of Aptiom by the FDA, the first Portuguese drug to ever to be approved in the…
Fransisco Velez, Founder and Director General of toLife, discusses the challenges facing generics companies in Portugal today, and his ambitions to further grow his company over the years to…
João Madeira, General Manager of Mylan Portugal provides an overview of the state of generics in Portugal today, discussing structural issues related to Portugal’s low generic medicines penetration, ways to…
Hernâni Sério, General Manager of the Portuguese affiliate, Fresenius Kabi, discusses the challenges of the hospital market, as well as his company’s strategic positioning in a market with few competitors…
As a company focused entirely on innovation, Janssen has remained dedicated to bringing groundbreaking new products to Portugal, ensuring access in Portugal is as stellar as anywhere else. Gisella Dante,…
Paulo Lilaia, CEO of Generis Portugal give an insight into the role of generics in the Portuguese marketplace as well as his company’s strategy to expand in both the local…
Cristina Campos, CPO Head and Country President of Novartis Portugal talks about the challenges surrounding market access in Portugal, as well as the affiliate’s strong investments in the country to…
Mario Martins, General Manager of Cegedim Portugal discusses the changes that his affiliate has made to adapt to the new realities of the Portuguese marketplace, and explains how a business…
Nelson Pires, General Manager of Jaba Recordati, the Portuguese affiliate of the Recordati Group, outlines the affiliate’s expansion into the PALOPS markets and demonstrates how the company has grown during…
Joaquim Cunha, Executive Director of Health Cluster Portugal (HCP), emphasizes Portugal’s need to discover niches in which the country can excel and compete globally, while rebranding its image around the…
Nuno Arantes-Oliveira, President of P-BIO, Portugal’s Biotechnology Industry Organization, the country’s sole association for biotechnology companies, discusses the state of the biotech industry today in Portugal, and the ways in…
Despite Portugal’s economic woes, some local companies have been able to adjust accordingly and succeed in this environment. Tecnifar is no exception. The company’s CEO, António Chaves Costa, talks about…
Pedro Ferraz da Costa, CMO Iberfar’s president, discusses generic competition in Portugal, his company’s expansion into Angola and southern Africa, and the company’s competitive advantages with its various subsidiaries. There…
See our Cookie Privacy Policy Here
